Search results
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
Morningstar· 5 days agoMedia Release Data from efti in combination with KEYTRUDA® in first line head and neck squamous cell carcinoma patients who do not express ...
Your expert guide to melanomas and how to spot them
The Telegraph via Yahoo News· 3 days agoIf you have noticed a lingering spot somewhere on your skin, it would be wise not to dismiss it, especially if there’s something unusual about its...
What Is Pancreatic Cancer?
Health via Yahoo News· 7 days agoHowever, treatments like surgery, radiation therapy, and chemotherapy can help shrink the tumor... are two main types of pancreatic cancer, based on the...
Tongue Cancer: Everything You Need to Know
Verywell Health via Yahoo News· 7 days agoTongue cancer, a type of oral cancer, often begins as a painful lump or sore on the side of the tongue that may bleed and resist healing. Here’s what to...
Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?
Benzinga via Yahoo Finance· 5 days agoThe investigational immuno-oncology combination demonstrates an overall response rate (ORR) of 26.9%...
EU regulators approve BeiGene's tislelizumab for lung cancer (NASDAQ:BGNE)
Seeking Alpha· 6 days agoEU regulators have approved BeiGene’s (NASDAQ:BGNE) tislelizumab for the treatment of three types of...
H.C. Wainwright Cuts HOOKIPA Pharma Shares target on Narrower HB-200 Target Population By...
Investing.com· 3 days agoThe adjustment followed HOOKIPA Pharma's announcement regarding the trial design of a Phase 2/3...
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
Morningstar· 4 days agoThe NDA is supported by results from JUPITER-02, a randomized, double-blind, placebo-controlled, multinational...
Analysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?
Investor's Business Daily· 5 days agoOverall, 27.3% responded to the treatment. A total of 63.6% of patients had their disease under...
Immutep Shares Rise 12% After Positive Data From Eftilagimod Trial
Market Watch· 5 days agoImmutep Limited shares were up 12% at $2.82 after the company said it saw positive preliminary topline results from its Phase IIb trial evaluating eftilagimod alpha, or efti, in combination ...
